Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Fangzhou Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$4.42 |
52 Week High | HK$6.71 |
52 Week Low | HK$3.78 |
Beta | 0 |
11 Month Change | 3.27% |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -2.43% |
Recent News & Updates
Recent updates
Shareholder Returns
6086 | HK Consumer Retailing | HK Market | |
---|---|---|---|
7D | -5.2% | -1.9% | -4.3% |
1Y | n/a | -45.1% | -2.8% |
Return vs Industry: Insufficient data to determine how 6086 performed against the Hong Kong Consumer Retailing industry.
Return vs Market: Insufficient data to determine how 6086 performed against the Hong Kong Market.
Price Volatility
6086 volatility | |
---|---|
6086 Average Weekly Movement | 14.4% |
Consumer Retailing Industry Average Movement | 6.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in HK Market | 13.2% |
10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 6086's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 6086's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 515 | Fangmin Xie | Jianke.com |
Fangzhou Inc. provides online chronic disease management services in China. The company provides services through online chronic disease management platform to address the needs of patients with chronic disease, such as hypertension, cardiovascular and respiratory chronic diseases. It offers H2H services, including online medical consultation services, e-prescription, and prescription refill services through mobile application; and healthcare products through online retail pharmacy service platform, as well as operates hospitals and offline pharmacies.
Fangzhou Inc. Fundamentals Summary
6086 fundamental statistics | |
---|---|
Market cap | HK$5.92b |
Earnings (TTM) | -HK$943.98m |
Revenue (TTM) | HK$2.70b |
2.2x
P/S Ratio-6.3x
P/E RatioIs 6086 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6086 income statement (TTM) | |
---|---|
Revenue | CN¥2.47b |
Cost of Revenue | CN¥1.96b |
Gross Profit | CN¥505.95m |
Other Expenses | CN¥1.37b |
Earnings | -CN¥861.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.64 |
Gross Margin | 20.52% |
Net Profit Margin | -34.94% |
Debt/Equity Ratio | -100.8% |
How did 6086 perform over the long term?
See historical performance and comparison